erlotinib hydrochloride has been researched along with diallyl trisulfide in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (diallyl trisulfide) | Trials (diallyl trisulfide) | Recent Studies (post-2010) (diallyl trisulfide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 332 | 4 | 205 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | diallyl trisulfide (IC50) |
|---|---|---|---|
| Fatty acid synthase | Gallus gallus (chicken) | 8.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Gu, Y; Jiang, X; Liu, Y | 1 |
1 other study(ies) available for erlotinib hydrochloride and diallyl trisulfide
| Article | Year |
|---|---|
Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Topics: Allyl Compounds; Animals; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Skin; Sulfides | 2019 |